WO1996027371A1 - Produit contre la carence - Google Patents

Produit contre la carence Download PDF

Info

Publication number
WO1996027371A1
WO1996027371A1 PCT/SE1996/000305 SE9600305W WO9627371A1 WO 1996027371 A1 WO1996027371 A1 WO 1996027371A1 SE 9600305 W SE9600305 W SE 9600305W WO 9627371 A1 WO9627371 A1 WO 9627371A1
Authority
WO
WIPO (PCT)
Prior art keywords
lysine
proline
substance
glycine
day
Prior art date
Application number
PCT/SE1996/000305
Other languages
English (en)
Inventor
Anders Jonsson
Original Assignee
A.K.J. Medikonsult Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A.K.J. Medikonsult Ab filed Critical A.K.J. Medikonsult Ab
Priority to AU49614/96A priority Critical patent/AU4961496A/en
Publication of WO1996027371A1 publication Critical patent/WO1996027371A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Definitions

  • the present application relates to a patent for Lysine, preferably 1-Lysine, as a substance to be administered in a deficiency condition resulting in collagen insufficiency in the mesodermal- ectodermal and endodermal tissue, and intended to undergo further development as a drug to be used for appropriate indications.
  • Lysine preferably 1-Lysine
  • the substance also contains Glycine, preferably 1- Glycine, and Proline, preferably 1-Proline, and is intended to provide the essential basic building block in collagen, i.e. the amino acid Lysine, preferably 1-Lysine, in a mixture with other building blocks Glycine, preferably 1-Glycine, and Proline, preferably 1-Proline, in order to substitute/repair deficiency conditions which predispose towards or establish generation in the collagen through the deficient reconstruction of, for example, mesodermal tissue systems consisting of or containing collagen. These tissue systems are encountered mainly in, for example, the cartilage, skeleton, tendons and muscle fasciae. Collagen is present in all supportive tissue, for example connective tissue in the skin and other ectodermal tissue.
  • connective tissue Apart from collagen fibres, connective tissue also contains thinner reticular fibrils and thinner elastic fibres, all with the same chemical building blocks Lysine, preferably 1-Lysine, Proline, preferably 1- Proline, and Glycine, preferably 1-Glycine.
  • Connective tissue/collagen is present not only in the mesoderm, endoderm and ectoderm, but also in the further development of the basic tissues into, for example neural grove, and its further differentiation into self-developing facial and cranial structures, the brain, the nervous system and the sensory organs of the skin, as well as maxillary-dental structures (periodontal and gingival structures) .
  • Collagen also occurs in mucous membranes and other endodermal tissues, for example the liver, lungs, airways and vessels, etc. A lack of collagen in the skeleton is probably a not insignificant component of osteoporosis (brittle bones) .
  • Certain of the peptides that are recommended contain both lysine, proline, glycine and other amino acids, although these are bonded as peptides and in compounds, including with fatty acids intended to increase their fat solubility and in so doing to make them more appealing in pharmaceutical or cosmetic creams and gels for application via the skin.
  • the method of administration of free L-acids is via the mouth or via the blood, which has an effect on the skin by building up the fibrils and fibres of the connective tissue from within, from the basic substrate administered via the mouth or the blood.
  • the preparation contains Quencetin esters of the amino acids Lysine, Proline and ascorbic acid and Quencetin esters of Valine, Isoleucine and Leucine in varying proportions up to a maximum of 100 per cent by weight. No glycine is present, however.
  • the preparation can be administered via the mouth, parenterally or locally. Oral application is preferred.
  • the description makes reference to the fact that the previously disclosed substance has also been found to be suitable for strengthening and stabilizing collagen in humans and animals.
  • the aforementioned uses include as treatment for sprained muscles, muscle rupture and intervertebral disc pain and intervertebral disc protrusion.
  • lysine, proline and glycine which in the present invention are administered as free amino acids and serve as a specific substrate for the formation of collagen fibre in endodermal, mesodermal and ectodermal tissues.
  • the chemistry in the previously disclosed method is different because of the absence of glycine, an important building block in collagen.
  • the muscle tissue lies entirely outside, and the disk lies largely outside the scope of the present invention.
  • the present invention includes sinews and ligaments, for example, including in the back surrounding the discs.
  • a male aged 63 years was given approx. 50-150 mg o 1-Lysine daily for a period of 6 months, plus ample substitution of all essential amino acids.
  • the basic illness was pronounced chondroma in one knee, which had been diagnosed by arthroscopy in the spring of 1994. There was a significant improvement after 3 months. After 6 months, the patient's walking distance increased from 20-100 m to 6-8 km. Stability was restored in the knee and in the quadriceps sinew.
  • Lysine preferably 1-Lysine
  • Glycine preferably 1-Glycine, 50-5000 mg/day;
  • Proline preferably 1-Proline, 50-5000 mg/day.
  • Lysine preferably 1-Lysine
  • Glycine preferably 1-Glycine
  • Proline preferably 1-Proline
  • the appropriate dose is 300 - 3 000 mg/day, or even as much as 20 000 - 30 000 mg/day.
  • Form tablets, powder, food additive or food modification (powder) , liquid form.
  • the substance may be administered parenterally, e.g. via the blood, or it may be injected locally particularly where certain indications are present.
  • Lysine preferably 1-Lysine
  • Proline preferably 1-Proline
  • the patent represents a novel concept in the sense that fibrosis is regarded as a shrinking process involving organs/connective tissue/collagen.
  • tissue shrinkage - fibrosis - also appears to be subject to a reversible deficiency in the building substrate of the collagen, Lysine, preferably 1-Lysine, Proline, preferably 1- Proline, and Glycine, preferably 1-Glycine.
  • Lysine, preferably 1-Lysine, Proline, preferably 1-Proline, and Glycine, preferably 1-Glycine can also restrict capsule formation, for example around foreign bodies, tumours or other tissue formations.
  • the invention is based on the principle that
  • Lysine preferably 1-Lysine, Proline, preferably 1-Proline, and Glycine, preferably 1-Glycine, also act as building blocks not only in collagen as a product of the fibroblasts in the collagen fibre, but also in the thinner fibres such as reticular fibre and elastic fibre.
  • the fibroblast can be differentiated as, for example, osteoblast, chondroblast, odontoblast (i.e. the one responsible for the formation of differentiated dental substance) and the fibroblast present in the peridontium and the gingiva.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une substance destinée à être administrée en cas de carence, avec comme corollaire une insuffisance en collagène dans les tissus mésodermiques, ectodermiques et endodermiques, ou destinée à la prévention de l'état de carence précité, et destinée à être développée en tant que médicament à utiliser dans des indications appropriées. L'acide aminé Lysine, de préférence 1-Lysine, est présent dans la substance précitée, et ladite substance contient également de la Glycine, de préférence de la 1-Glycine, et de la Proline, de préférence de la 1-Proline, sous forme d'un mélange.
PCT/SE1996/000305 1995-01-25 1996-03-08 Produit contre la carence WO1996027371A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU49614/96A AU4961496A (en) 1995-01-25 1996-03-08 Product against deficiency

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9500270A SE9500270L (sv) 1995-01-25 1995-01-25 Läkemedel mot bristtillstånd
SE9500270-5 1995-03-08

Publications (1)

Publication Number Publication Date
WO1996027371A1 true WO1996027371A1 (fr) 1996-09-12

Family

ID=20396965

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1996/000305 WO1996027371A1 (fr) 1995-01-25 1996-03-08 Produit contre la carence

Country Status (3)

Country Link
AU (1) AU4961496A (fr)
SE (1) SE9500270L (fr)
WO (1) WO1996027371A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025972A1 (fr) * 1996-01-17 1997-07-24 Friedrich Kisters Preparation pour stimuler la pousse des cheveux, ameliorer la structure de la peau et/ou regenerer les ongles
EP1010427A1 (fr) * 1998-12-18 2000-06-21 Solartium Establishment Composition pharmaceutique à base de proline, glysine et lysine, utile pour les traitement dentaires, se présentant sous forme injectable ou pour un usage topique
WO2002064131A2 (fr) * 2001-02-14 2002-08-22 Thomas Luger Composes inhibant les inflammations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012441A1 (fr) * 1988-06-16 1989-12-28 Procyte Corporation Preparations cosmetiques et pour les soins de la peau
US5198465A (en) * 1991-06-19 1993-03-30 Dioguardi Francesco S Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen
DE4243363A1 (de) * 1992-12-21 1994-06-23 Ulrich Dr Med Kuebler Behandlungsverfahren für Hauttrockenheit
DE4243362A1 (de) * 1992-12-21 1994-06-23 Ulrich Dr Med Kuebler Mittel zur Behandlung von Hauttrockenheit, des Neuroendokriniums und Immunsystems

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012441A1 (fr) * 1988-06-16 1989-12-28 Procyte Corporation Preparations cosmetiques et pour les soins de la peau
US5198465A (en) * 1991-06-19 1993-03-30 Dioguardi Francesco S Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen
DE4243363A1 (de) * 1992-12-21 1994-06-23 Ulrich Dr Med Kuebler Behandlungsverfahren für Hauttrockenheit
DE4243362A1 (de) * 1992-12-21 1994-06-23 Ulrich Dr Med Kuebler Mittel zur Behandlung von Hauttrockenheit, des Neuroendokriniums und Immunsystems

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025972A1 (fr) * 1996-01-17 1997-07-24 Friedrich Kisters Preparation pour stimuler la pousse des cheveux, ameliorer la structure de la peau et/ou regenerer les ongles
US6331569B1 (en) 1996-01-17 2001-12-18 Friedrich Kisters Preparation for improving hair growth, the skin structure and/or nail regeneration
EP1010427A1 (fr) * 1998-12-18 2000-06-21 Solartium Establishment Composition pharmaceutique à base de proline, glysine et lysine, utile pour les traitement dentaires, se présentant sous forme injectable ou pour un usage topique
US6270750B1 (en) 1998-12-18 2001-08-07 Solartium Establishment Proline-, glycine- and lysine-based pharmaceutical composition useful in dental treatment both in the injectable form and in the formulation for topical use
WO2002064131A2 (fr) * 2001-02-14 2002-08-22 Thomas Luger Composes inhibant les inflammations
WO2002064131A3 (fr) * 2001-02-14 2004-04-01 Thomas Luger Composes inhibant les inflammations
US8003608B2 (en) 2001-02-14 2011-08-23 Thomas Luger Inflammation-inhibiting compounds
CN101810847B (zh) * 2001-02-14 2013-02-13 托马斯·卢格尔 抑制炎症的化合物
US8846617B2 (en) 2001-02-14 2014-09-30 Thomas Luger Inflammation inhibiting compounds
US9550807B2 (en) 2001-02-14 2017-01-24 Thomas Luger Inflammation inhibiting compounds
US10046020B2 (en) 2001-02-14 2018-08-14 Thomas Luger Inflammation inhibiting compounds

Also Published As

Publication number Publication date
SE9500270D0 (sv) 1995-01-25
SE9500270L (sv) 1996-09-09
AU4961496A (en) 1996-09-23

Similar Documents

Publication Publication Date Title
US6780841B2 (en) Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same
CA1261263A (fr) Traitement de maladies inflammatoires degeneratives
US4772591A (en) Method for accelerated wound healing
CA1302880C (fr) Agents pour le traitement de l'arthrose
US8080535B2 (en) Hyaluronic acid nutritional supplements and methods of using the same
JPH10504555A (ja) 無味の加水分解コラーゲンの使用及びそれを含む薬剤
EP1083915B1 (fr) Compositions contenant du molybdene destine a favoriser l'anabolisme des proteines et la detoxication
US20240358743A1 (en) Cosmetic/dermatological composition
EP1273239B1 (fr) Utilisations d'une composition de gélatine de poisson partiellement hydrolysée
US6620836B1 (en) Antiarrhythmic and tranquilizer composition and treatment
CN110327404B (zh) 一种干眼症保湿喷雾剂及其制备方法
Lobo et al. Use of Theraflex-TMJ topical cream for the treatment of temporomandibular joint and muscle pain
WO1996027371A1 (fr) Produit contre la carence
CN108815505B (zh) 提高中老年人骨密度和骨关节功能避免腰腿抽筋的组合物
EP0841895B1 (fr) Creme amincissante a base de plantes
US20200030349A1 (en) Physiologically active preparation comprising n-acetyl-glucosamine for the treatment of back pain
WO1989009604A1 (fr) Supplement de soufre mineral alimentaire
RU2268052C2 (ru) Средство для лечения воспалительных и дегенеративных заболеваний суставов (варианты), способ лечения воспалительных и дегенеративных заболеваний суставов (варианты) и устройство для доставки лекарственного средства к пораженному участку
JP2002284668A (ja) クスミの予防・治療剤
CN108719998A (zh) 一种用于治疗骨关节炎的口服膳食补充药剂
JPS5962528A (ja) 疲労回復剤
CN115282137B (zh) 一种外用擦剂护理组合物及其制备方法
CN118490890B (zh) 一种抗皱复方注射液及其制备方法和应用
WO2009031922A1 (fr) Comprimé pour la prophylaxie et le traitement de maladies dentaires et périodontaires
EP0197898B1 (fr) Composition à base de gélatine et de glycine contre la déshydratation de la peau

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase